Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced NSCLC: a network meta-analysis

Programmed death 1 (PD-1)/programmed death 1 ligand 1 (PD-L1)-directed immunotherapy has revolutionized the treatments for advanced non-small cell lung cancer (NSCLC), whereas the optimal therapeutic combinations remain uncertain.